https://aptar.com/en-us/resources/annex-1-and-elastomeric-closures-evolving-considerations 2026-05-26T14:37:47Z 0.5 https://aptar.com/en-us/resources/glp-1-at-scale-elastomeric-closure-decisions-that-are-hard-to-postpone 2026-05-21T19:13:24Z 0.5 https://aptar.com/en-us/resources/small-yet-impactful-simplicycle-recyclable-valve-white-paper 2026-05-21T18:44:13Z 0.5 https://aptar.com/en-us/resources/low-gwp-pmdis-evolving-a-proven-inhaler-platform-for-sustainability 2026-05-21T16:52:16Z 0.5 https://aptar.com/en-us/resources/aptar-s-code-of-conduct-2026 2026-05-15T14:23:43Z 0.5 https://aptar.com/en-us/resources/elastomeric-closures-for-biosimilars-the-same-rules-with-reduced-tolerance-for-gaps 2026-05-15T12:00:59Z 0.5 https://aptar.com/en-us/resources/injectable-primary-packaging-complies-with-annex-1-revision 2026-05-14T20:09:45Z 0.5 https://aptar.com/en-us/resources/advancing-nose-to-brain-delivery-with-intranasal-platforms 2026-04-30T11:19:48Z 0.5 https://aptar.com/en-us/resources/reducing-pharmas-scope-3-emissions-with-low-gwp-pmdis 2026-04-07T20:39:03Z 0.5 https://aptar.com/en-us/resources/climate-transition-plan-2025 2026-04-07T20:37:56Z 0.5 https://aptar.com/en-us/resources/glp-1-drug-development-leveraging-integrated-solutions-to-improve-patient-engagement 2026-04-06T22:00:41Z 0.5 https://aptar.com/en-us/resources/understanding-net-zero-and-carbon-neutrality 2026-03-10T22:00:15Z 0.5 https://aptar.com/en-us/resources/aptar-beauty-releases-covid-19-foresight-study 2026-03-05T21:51:08Z 0.5 https://aptar.com/en-us/resources/how-aptar-beauty-leverages-in-house-ista-6-certification-testing-to-drive-faster-time-to-market-for-omnichannel-packaging-innovations 2026-03-05T21:39:58Z 0.5 https://aptar.com/en-us/resources/how-to-transform-beauty-packaging-from-linear-to-circular-economy 2026-03-05T21:35:34Z 0.5 https://aptar.com/en-us/resources/making-beauty-more-inclusive 2026-03-05T21:28:20Z 0.5 https://aptar.com/en-us/resources/inclusive-packaging-design-guide 2026-03-05T21:24:56Z 0.5 https://aptar.com/en-us/resources/aptars-sustainable-purchasing-charter 2026-03-05T15:44:48Z 0.5 https://aptar.com/en-us/resources/in-vitro-anatomical-models-for-nasal-drug-delivery 2026-02-24T17:50:14Z 0.5 https://aptar.com/en-us/resources/together-taking-innovation-sustainability-to-new-heights 2026-02-12T14:53:42Z 0.5 https://aptar.com/en-us/resources/aptar-continues-to-provide-essential-products-during-covid-19-pandemic 2026-02-12T14:52:30Z 0.5 https://aptar.com/en-us/resources/the-new-imperative 2026-02-10T21:45:00Z 0.5 https://aptar.com/en-us/resources/supporting-patients-and-hcps-with-new-digital-technology 2026-02-10T21:43:46Z 0.5 https://aptar.com/en-us/resources/enabling-a-sustainable-future-through-packaging-innovation 2026-02-10T21:43:13Z 0.5 https://aptar.com/en-us/resources/take-the-next-step-on-your-brands-sustainability-journey 2026-02-10T21:42:10Z 0.5 https://aptar.com/en-us/resources/failure-to-start-filling-the-cracks-covid-exposed-in-patient-onboarding-support-to-enable-successful-new-therapy-initiations-in-an-uncertain-world 2026-02-10T21:40:40Z 0.5 https://aptar.com/en-us/resources/all-the-buzz 2026-02-10T21:38:39Z 0.5 https://aptar.com/en-us/resources/2014-voice-of-customer-survey-results 2026-02-10T21:38:03Z 0.5 https://aptar.com/en-us/resources/climate-transition-plan-2024 2026-02-10T21:36:35Z 0.5 https://aptar.com/en-us/resources/safe-trustworthy 2026-02-10T21:35:52Z 0.5 https://aptar.com/en-us/resources/an-easier-way-to-get-your-vitamin-c 2026-02-10T21:35:27Z 0.5 https://aptar.com/en-us/resources/sustainable-propellants-and-bioequivalence-innovation-in-oindps 2026-02-10T21:34:27Z 0.5 https://aptar.com/en-us/resources/spray-dried-formulations-for-nasal-applications-challenges-and-opportunities-in-filling-and-drug-delivery 2026-02-10T21:33:41Z 0.5 https://aptar.com/en-us/resources/nasal-drug-delivery-past-present-and-future-perspectives 2026-02-10T21:33:06Z 0.5 https://aptar.com/en-us/resources/development-of-in-vitro-nasal-cast-imaging-techniques-to-predict-in-vivo-nasal-deposition 2026-02-10T21:32:30Z 0.5 https://aptar.com/en-us/resources/evaluation-of-albuterol-sulfate-with-low-global-warming-potential-propellants 2026-02-10T21:31:50Z 0.5 https://aptar.com/en-us/resources/interview-with-digital-health-experts-sai-shankar-adam-shain-and-marcus-bates 2026-02-10T21:31:11Z 0.5 https://aptar.com/en-us/resources/dose-and-delivery-how-pmdis-are-transforming-asthma-and-copd-treatments 2026-02-10T21:29:48Z 0.5 https://aptar.com/en-us/resources/supporting-improved-patient-onboarding-and-adherence-with-training-solutions 2026-02-10T21:29:15Z 0.5 https://aptar.com/en-us/resources/overview-of-intranasal-drug-administration-using-multi-dose-nasal-spray-pumps 2026-02-10T21:28:34Z 0.5 https://aptar.com/en-us/resources/approaches-to-extractables-and-leachables-in-parenteral-drugs 2026-02-10T21:28:01Z 0.5 https://aptar.com/en-us/resources/patient-focused-cancer-care-harnessing-immunotherapy 2026-02-10T21:27:35Z 0.5 https://aptar.com/en-us/resources/meeting-the-worlds-evolving-needs-for-a-more-sustainable-future-how-to-realize-a-circular-approach-to-drug-delivery-solutions 2026-02-10T21:26:58Z 0.5 https://aptar.com/en-us/resources/drug-repurposing-broadening-patient-accessibility-via-a-change-in-drug-delivery-system 2026-02-10T21:26:10Z 0.5 https://aptar.com/en-us/resources/developing-an-in-vitro-dissolution-and-release-system-for-orally-inhaled-drug-products 2026-02-10T21:25:34Z 0.5 https://aptar.com/en-us/resources/in-vitro-and-in-vivo-assessment-of-regional-nasal-deposition-using-scintigraphy-from-a-nasal-spray-and-a-nasal-powder 2026-02-10T21:25:01Z 0.5 https://aptar.com/en-us/resources/improving-patient-adherence-and-compliance-with-innovative-digital-healthcare-solutions 2026-02-10T21:24:24Z 0.5 https://aptar.com/en-us/resources/how-emotional-intelligence-is-driving-improvements-and-meeting-the-challenges-in-pulmonary-drug-delivery 2026-02-10T21:23:58Z 0.5 https://aptar.com/en-us/resources/optimizing-patient-outcomes-in-respiratory-medicine-with-digital-healthcare-devices 2026-02-10T21:23:14Z 0.5 https://aptar.com/en-us/resources/successfully-balancing-the-needs-of-the-planet-with-the-needs-of-the-patient 2026-02-10T21:22:46Z 0.5 https://aptar.com/en-us/resources/drug-repurposing-a-more-efficient-approach-to-drug-development 2026-02-10T21:22:11Z 0.5 https://aptar.com/en-us/resources/how-digital-healthcare-solutions-could-improve-patient-compliance-and-adherence 2026-02-10T21:21:48Z 0.5 https://aptar.com/en-us/resources/exploring-nasal-casts-in-nasal-drug-development 2026-02-10T21:21:23Z 0.5 https://aptar.com/en-us/resources/connected-devices-digital-health-and-digital-therapeutics-where-are-we-heading-and-why 2026-02-10T21:20:52Z 0.5 https://aptar.com/en-us/resources/the-control-everyone-asked-for 2026-02-10T21:20:25Z 0.5 https://aptar.com/en-us/resources/the-need-to-scale-up-digital-health-in-the-post-covid-world 2026-02-10T21:19:54Z 0.5 https://aptar.com/en-us/resources/advanced-stopper-solution-premiumcoat-proven-compatibility-with-current-vial-standards 2026-02-10T21:19:09Z 0.5 https://aptar.com/en-us/resources/nanoparticle-formulation-strategies-for-intranasal-drug-delivery 2026-02-10T21:18:35Z 0.5 https://aptar.com/en-us/resources/towards-a-new-standard-of-care-with-aptar-pharmas-digital-health 2026-02-10T21:17:55Z 0.5 https://aptar.com/en-us/resources/interview-with-guillaume-brouet-on-aptar-pharma-services 2026-02-10T21:17:22Z 0.5 https://aptar.com/en-us/resources/ocular-drug-delivery-an-interesting-past-with-a-fascinating-future 2026-02-10T21:16:50Z 0.5 https://aptar.com/en-us/resources/moving-toward-a-more-sustainable-future-with-pmdis 2026-02-10T21:16:25Z 0.5 https://aptar.com/en-us/resources/is-now-the-time-to-shake-up-the-pmdi-environment 2026-02-10T21:13:16Z 0.5 https://aptar.com/en-us/resources/ensuring-container-integrity-at-various-temperatures 2026-02-10T21:12:45Z 0.5 https://aptar.com/en-us/resources/covid-19-drug-delivery-options-to-succeed-sooner 2026-02-10T21:12:21Z 0.5 https://aptar.com/en-us/resources/the-go-to-drug-delivery-expert 2026-02-10T21:11:54Z 0.5 https://aptar.com/en-us/resources/exploring-extractable-and-leachable-testing-strategies-for-parenterals 2026-02-10T21:11:18Z 0.5 https://aptar.com/en-us/resources/characterizing-and-controlling-foreign-particulate-matters-fpm 2026-02-10T21:10:40Z 0.5 https://aptar.com/en-us/resources/building-digital-solutions-to-meet-the-unique-therapeutic-needs-of-patients 2026-02-10T21:10:14Z 0.5 https://aptar.com/en-us/resources/optimizing-your-pre-clinical-discovery-in-pulmonary-nasal-drug-development 2026-02-10T21:09:42Z 0.5 https://aptar.com/en-us/resources/breaking-new-grounds-in-nutritional-supplements 2026-02-10T21:09:15Z 0.5 https://aptar.com/en-us/resources/using-bioequivalence-and-particle-size-distribution-to-develop-oindps 2026-02-10T21:08:49Z 0.5 https://aptar.com/en-us/resources/airless-drug-delivery-widely-accepted-accessible-and-available 2026-02-10T21:08:20Z 0.5 https://aptar.com/en-us/resources/the-potential-of-digital-health-in-empowering-patients-with-cancer 2026-02-10T21:07:48Z 0.5 https://aptar.com/en-us/resources/new-tools-to-advance-cns-drug-delivery 2026-02-10T21:07:22Z 0.5 https://aptar.com/en-us/resources/rethinking-oral-solid-dose-packaging 2026-02-10T21:06:56Z 0.5 https://aptar.com/en-us/resources/training-devices-and-patient-education-play-a-crucial-role-in-the-self-injection-drug-delivery-market 2026-02-10T21:06:30Z 0.5 https://aptar.com/en-us/resources/pharmacokinetic-profiling-in-the-development-of-a-generic-tiotropium-dry-powder-inhaler 2026-02-10T21:05:48Z 0.5 https://aptar.com/en-us/resources/orally-inhaled-drug-products-bioequivalence-models 2026-02-10T21:05:11Z 0.5 https://aptar.com/en-us/resources/investigation-of-powder-blend-uniformity-and-deposition-in-a-nasal-cast-using-a-unit-dose-nasal-system 2026-02-10T21:04:37Z 0.5 https://aptar.com/en-us/resources/development-of-a-novel-nasal-spray-containing-human-recombinant-antibody-for-sars-cov-2-therapy 2026-02-10T21:04:07Z 0.5 https://aptar.com/en-us/resources/consistent-experience-with-dosing 2026-02-10T21:03:34Z 0.5 https://aptar.com/en-us/resources/systemic-nasal-drug-delivery-for-cns-diseases-and-beyond 2026-02-10T21:00:02Z 0.5 https://aptar.com/en-us/resources/overcoming-the-challenges-in-developing-an-in-vitro-dissolution-and-release-system-for-orally-inhaled-drug-products 2026-02-10T20:59:06Z 0.5 https://aptar.com/en-us/resources/delivering-nasally-administered-biologics 2026-02-10T20:57:59Z 0.5 https://aptar.com/en-us/resources/physiologically-based-pharmacokinetic-models-pbpk-for-oindps 2026-02-10T20:57:23Z 0.5 https://aptar.com/en-us/resources/enhancing-the-patient-experience-for-self-injection-systems 2026-02-10T20:56:50Z 0.5 https://aptar.com/en-us/resources/decoding-the-fdas-recent-combination-drug-product-guidance-applications-to-dpis-pmdis-and-nasal-sprays 2026-02-10T20:56:16Z 0.5 https://aptar.com/en-us/resources/how-evolving-patient-needs-have-fuelled-the-development-of-nasal-drug-delivery 2026-02-10T20:55:51Z 0.5 https://aptar.com/en-us/resources/a-new-purpose-drug-repurposing 2026-02-10T20:55:14Z 0.5 https://aptar.com/en-us/resources/comparison-of-pulmonary-deposition-for-single-and-multidose-dry-powder-inhalers-with-indacaterol-and-glycopyrrolate 2026-02-10T20:54:40Z 0.5 https://aptar.com/en-us/resources/end-to-end-support-at-every-stage-of-your-drug-development-journey 2026-02-10T20:53:51Z 0.5 https://aptar.com/en-us/resources/the-current-state-of-play-in-connected-devices 2026-02-10T20:53:15Z 0.5 https://aptar.com/en-us/resources/towards-a-more-sustainable-future-with-metered-dose-inhalers 2026-02-10T20:52:41Z 0.5 https://aptar.com/en-us/resources/decoding-article-117-of-medical-device-regulation-2017-745-as-applicable-to-integral-drug-device-combination-products 2026-02-10T20:52:16Z 0.5 https://aptar.com/en-us/resources/developing-a-dry-powder-formulation-for-aptar-pharma-prohaler 2026-02-10T20:51:48Z 0.5 https://aptar.com/en-us/resources/striving-for-a-more-circular-pharmaceutical-industry-how-aptar-pharma-can-support-your-sustainability-journey 2026-02-10T20:51:16Z 0.5 https://aptar.com/en-us/resources/drug-device-digital-reimagined-healthcare 2026-02-10T20:50:37Z 0.5 https://aptar.com/en-us/resources/exploring-a-faster-more-cost-effective-alternative-to-generic-bioequivalence 2026-02-10T20:50:07Z 0.5 https://aptar.com/en-us/resources/the-importance-of-training-and-onboarding-for-intranasal-rescue-treatments 2026-02-10T20:49:31Z 0.5 https://aptar.com/en-us/resources/investigating-the-pharmacokinetic-properties-of-fluticasone-dry-powder-inhaler 2026-02-10T20:48:57Z 0.5 https://aptar.com/en-us/resources/good-medicine-solutions-for-sensitive-injectable-formulations 2026-02-10T20:48:06Z 0.5 https://aptar.com/en-us/resources/devices-services-for-lifecycle-management-of-crisis-medications-and-beyond 2026-02-10T20:47:35Z 0.5 https://aptar.com/en-us/resources/using-raman-spectroscopy-for-characterizing-nasal-suspension-drug-products 2026-02-10T20:47:02Z 0.5 https://aptar.com/en-us/resources/advancements-in-targeted-drug-delivery-for-nasal-and-pulmonary-devices 2026-02-10T20:46:26Z 0.5 https://aptar.com/en-us/resources/sustainability-at-the-heart-of-aptar-pharmas-expansion 2026-02-10T20:44:12Z 0.5 https://aptar.com/en-us/resources/how-to-rapidly-formulate-select-a-device-and-develop-a-novel-concept-for-nasal-and-pulmonary-drug-delivery 2026-02-10T20:37:16Z 0.5 https://aptar.com/en-us/resources/analysis-of-fluticasones-physiologic-and-pharmacokinetic-properties 2026-02-10T20:36:38Z 0.5 https://aptar.com/en-us/resources/pharma-partnering-considerations-for-injectable-device-components 2026-02-10T20:36:01Z 0.5 https://aptar.com/en-us/resources/investigation-of-in-vitro-dissolution-tests-for-orally-inhaled-drug-products 2026-02-10T20:35:11Z 0.5 https://aptar.com/en-us/resources/evaluating-the-particle-distribution-for-dry-powder-inhalers 2026-02-10T20:34:31Z 0.5 https://aptar.com/en-us/resources/otimizacao-de-processos-no-desenvolvimento-de-produtos-inalatorios-orais-e-nasais 2026-02-10T20:33:49Z 0.5 https://aptar.com/en-us/resources/extractables-leachables-for-injectable-formulations 2026-02-10T20:32:54Z 0.5 https://aptar.com/en-us/resources/advancing-oindp-clinical-trials-with-speed-and-efficiency-strategies-for-success 2026-02-10T20:32:17Z 0.5 https://aptar.com/en-us/resources/improving-intranasal-sprays-for-respiratory-viral-infections 2026-02-10T20:31:37Z 0.5 https://aptar.com/en-us/resources/enhanced-injection-experience-with-pre-filled-syringe-solutions 2026-02-10T20:30:59Z 0.5 https://aptar.com/en-us/resources/applying-connectivity-to-enhance-the-training-standard-of-care-for-self-injection 2026-02-10T20:28:30Z 0.5 https://aptar.com/en-us/resources/connected-medicine-insights-from-payers-and-other-stakeholders 2026-02-10T20:27:55Z 0.5 https://aptar.com/en-us/resources/in-silico-modelling-for-orally-inhaled-drug-development-oindp 2026-02-10T20:27:17Z 0.5 https://aptar.com/en-us/resources/connected-health-an-effective-solution-to-improve-patient-adherence 2026-02-10T20:26:51Z 0.5 https://aptar.com/en-us/resources/usp-382-a-shift-in-injectable-packaging-requirements 2026-02-10T20:26:02Z 0.5 https://aptar.com/en-us/resources/overview-of-microbial-integrity-tests-for-preservative-free-nasal-spray-pumps-and-multidose-eyedroppers 2026-02-10T20:25:21Z 0.5 https://aptar.com/en-us/resources/optimizing-preclinical-studies-for-intranasal-and-pulmonary-programs 2026-02-10T20:24:46Z 0.5 https://aptar.com/en-us/resources/orbital-a-novel-dry-powder-inhaler-for-high-dose-delivery 2026-02-10T20:24:18Z 0.5 https://aptar.com/en-us/resources/delivery-of-biologics-to-the-nasal-cavity-the-future-of-nasal-drug-delivery 2026-02-10T20:23:55Z 0.5 https://aptar.com/en-us/resources/investigating-storage-options-for-pressurized-metered-dose-inhalers 2026-02-10T20:23:29Z 0.5 https://aptar.com/en-us/resources/investigating-breathable-hpv-l2-dry-powder-vaccine-using-gla-as-amphiphilic-lubricant-and-immune-adjuvant 2026-02-10T20:22:54Z 0.5 https://aptar.com/en-us/resources/raising-the-bar-for-injectable-drugs-eu-gmp-annex-1-primary-packaging-considerations 2026-02-10T20:22:20Z 0.5 https://aptar.com/en-us/resources/aptar-pharma-vaccine-platform-addresses-covid-19-development-life-cycle-management 2026-02-10T20:21:57Z 0.5 https://aptar.com/en-us/resources/purehale-the-future-of-fine-mist-dispensers-for-upper-airway-treatments 2026-02-10T20:21:23Z 0.5 https://aptar.com/en-us/resources/investigating-the-propellant-pathways-leading-to-a-sustainable-future-of-mdis 2026-02-10T20:20:49Z 0.5 https://aptar.com/en-us/resources/acceptability-of-cyltezo-pen-among-patients-and-healthcare-professionals 2026-02-10T20:20:11Z 0.5 https://aptar.com/en-us/resources/quality-safety-regulatory-compliance-for-elastomeric-closures 2026-02-10T20:19:36Z 0.5 https://aptar.com/en-us/resources/elevating-medication-adherence-and-clinical-outcomes-with-connected-drug-delivery 2026-02-10T20:18:59Z 0.5 https://aptar.com/en-us/resources/premiumcoat-solutions-helping-control-the-level-of-silicone-to-protect-sensitive-therapeutics 2026-02-10T20:18:25Z 0.5 https://aptar.com/en-us/resources/step-to-success-in-nose-to-brain-drug-delivery 2026-02-10T20:17:45Z 0.5 https://aptar.com/en-us/resources/derisking-the-development-of-sensitive-injectables 2026-02-10T20:17:10Z 0.5 https://aptar.com/en-us/resources/a-new-test-method-to-establish-targeted-delivery-to-the-upper-respiratory-tract 2026-02-10T20:16:44Z 0.5 https://aptar.com/en-us/resources/exploring-a-novel-device-for-nasal-drug-delivery-to-the-olfactory-system 2026-02-10T20:16:14Z 0.5 https://aptar.com/en-us/resources/vial-stopper-compatibility-criteria-and-testing-methods 2026-02-10T20:15:37Z 0.5 https://aptar.com/en-us/resources/advanced-parenteral-closure-solutions-the-perfect-fit-towards-compliance-with-ema-gmp-annex-1-revision 2026-02-10T20:15:01Z 0.5 https://aptar.com/en-us/resources/case-study-bidose-nasal-spray-pump-for-depression 2026-02-10T20:14:34Z 0.5 https://aptar.com/en-us/resources/aptar-pharmas-virtual-showcase 2026-02-10T20:13:54Z 0.5 https://aptar.com/en-us/resources/aptar-pharmas-ready-to-use-program 2026-02-10T20:13:27Z 0.5 https://aptar.com/en-us/resources/advancing-glp-1-drug-developments-with-integrated-solutions 2026-02-10T20:12:51Z 0.5 https://aptar.com/en-us/resources/mission-possible-sustainability-in-pharmaceutical-primary-packaging 2026-02-10T20:12:27Z 0.5 https://aptar.com/en-us/resources/aptar-pharma-rfid-enabled-rigid-needle-shields-for-unit-serialization-track-and-trace 2026-02-10T20:12:00Z 0.5 https://aptar.com/en-us/resources/cold-storage-container-closure-integrity-demonstrated-performance-of-etfe-coated-components 2026-02-10T20:11:22Z 0.5 https://aptar.com/en-us/resources/premiumcoat-plunger-filling-lines-facilitates-sensitive-vaccines-biotech-drug-delivery 2026-02-10T20:10:48Z 0.5 https://aptar.com/en-us/resources/nasal-drug-delivery-trends-challenges-and-opportunities-for-therapeutic-innovation 2026-02-10T20:10:12Z 0.5 https://aptar.com/en-us/resources/derisking-the-development-of-prefilled-syringe-delivery 2026-02-10T20:09:28Z 0.5 https://aptar.com/en-us/resources/digital-health-and-oncology-innovations-in-subcutaneous-administration 2026-02-10T20:08:43Z 0.5 https://aptar.com/en-us/resources/eliminating-the-need-for-additives-in-multidose-preservative-free-eye-care-formulations 2026-02-10T20:08:08Z 0.5 https://aptar.com/en-us/resources/sustainability-measures-are-the-key-to-meeting-esg-commitments 2026-02-10T20:07:22Z 0.5 https://aptar.com/en-us/resources/the-pharmaceutical-industrys-role-in-the-global-environmental-sustainability-movement 2026-02-10T20:06:37Z 0.5 https://aptar.com/en-us/resources/advancing-nose-to-brain-drug-delivery-intranasal-administration-of-insulin 2026-02-10T20:04:28Z 0.5 https://aptar.com/en-us/resources/nasal-spray-orientation-sumatriptan-exposure-using-pk-modelling 2026-02-10T20:01:26Z 0.5 https://aptar.com/en-us/resources/coating-technology-combining-a-state-of-the-art-bromobutyl-formulation-with-a-proven-etfe-film-for-exceptional-chemical-performance 2026-02-10T20:00:49Z 0.5 https://aptar.com/en-us/resources/targeted-aerosol-delivery-to-nalt-using-bivax-intranasal-atomizer 2026-02-10T20:00:11Z 0.5 https://aptar.com/en-us/resources/navigating-the-development-for-orally-inhaled-and-nasal-drug-products 2026-02-10T19:59:39Z 0.5 https://aptar.com/en-us/resources/navigating-the-shift-to-more-sustainable-low-gwp-propellants-in-pmdis 2026-02-10T19:58:30Z 0.5 https://aptar.com/en-us/resources/understanding-pbpk-modeling-in-oindps-insights-from-will-ganley 2026-02-10T19:57:56Z 0.5 https://aptar.com/en-us/resources/case-study-unidose-nasal-spray-pump-for-epilepsy 2026-02-10T19:57:20Z 0.5 https://aptar.com/en-us/resources/an-eye-on-the-future-of-preservative-free-drops 2026-02-10T19:56:45Z 0.5 https://aptar.com/en-us/resources/a-pharmapack-europe-2022-preview-the-future-of-medical-devices 2026-02-10T19:56:13Z 0.5 https://aptar.com/en-us/resources/the-art-of-ccit-deterministic-method-selection 2026-02-10T19:55:46Z 0.5 https://aptar.com/en-us/resources/round-table-evolution-of-pressurized-metered-dose-inhalers-to-cut-carbon-emissions 2026-02-10T19:55:10Z 0.5 https://aptar.com/en-us/resources/aptar-pharma-expands-injectables-components-manufacturing-capabilities 2026-02-10T19:54:42Z 0.5 https://aptar.com/en-us/resources/why-pharma-should-care-about-circular-packaging-futurity-leading-the-way 2026-02-10T19:54:02Z 0.5 https://aptar.com/en-us/resources/case-study-the-airless-dermal-drug-delivery-system 2026-02-10T19:53:31Z 0.5 https://aptar.com/en-us/resources/ophthalmic-squeeze-dispenser-osd-does-one-size-fit-all 2026-02-10T19:52:57Z 0.5 https://aptar.com/en-us/resources/helping-millions-around-the-world-breathe-easier-every-day 2026-02-10T19:52:09Z 0.5 https://aptar.com/en-us/resources/ensuring-functional-performance-and-regulatory-compliance-of-elastomer-stoppers-for-multipiercing-situations 2026-02-10T19:51:13Z 0.5 https://aptar.com/en-us/resources/analytical-services-in-the-development-of-mdis-and-dpis 2026-02-10T19:50:39Z 0.5 https://aptar.com/en-us/resources/advanced-analysis-of-dry-powder-inhaler-formulations-for-bioequivalence 2026-02-10T19:50:03Z 0.5 https://aptar.com/en-us/resources/exploring-the-benefits-and-future-possibilities-of-nasal-drug-delivery-and-drug-repositioning 2026-02-10T19:44:10Z 0.5 https://aptar.com/en-us/resources/beyond-probability-choosing-deterministic-methods-for-container-closure-integrity-testing 2026-02-10T19:43:44Z 0.5 https://aptar.com/en-us/resources/optimizing-patient-adherence-and-compliance-in-eye-care 2026-02-10T19:43:06Z 0.5 https://aptar.com/en-us/resources/understanding-the-evolution-of-intranasal-vaccines 2026-02-10T19:42:37Z 0.5 https://aptar.com/en-us/resources/case-study-unidose-nasal-spray-pump-in-hypoglycemia 2026-02-10T19:42:06Z 0.5 https://aptar.com/en-us/resources/moving-towards-greater-recyclability-in-drug-delivery-sustainable-solutions-by-aptar-pharma 2026-02-10T19:41:14Z 0.5 https://aptar.com/en-us/resources/nasal-delivery-of-biologics-a-whole-new-ball-game 2026-02-10T19:40:46Z 0.5 https://aptar.com/en-us/resources/cyclosporine-a-micellar-nasal-spray-a-promising-antiviral-solution-against-sars-cov-2 2026-02-10T19:40:20Z 0.5 https://aptar.com/en-us/resources/leachables-assessment-new-pmdi-with-low-gwp-propellants 2026-02-10T19:39:41Z 0.5 https://aptar.com/en-us/resources/nasal-casts-tools-to-enable-nasal-drug-delivery-development 2026-02-10T19:39:06Z 0.5 https://aptar.com/en-us/resources/de-risking-combination-product-registration-for-semi-solids-with-aptar-pharma-airless-systems 2026-02-10T19:38:42Z 0.5 https://aptar.com/en-us/resources/pfs-and-autoinjector-drug-delivery-a-platform-of-primary-packaging-solutions-for-streamlined-delivery 2026-02-10T19:38:06Z 0.5 https://aptar.com/en-us/resources/from-formulation-to-patient-intranasal-administration-of-cns-therapeutics 2026-02-10T19:37:37Z 0.5 https://aptar.com/en-us/resources/exploring-systemic-nasal-delivery-device-formulation 2026-02-10T19:37:11Z 0.5 https://aptar.com/en-us/resources/using-intranasal-delivery-for-drug-repositioning-a-compelling-proposition-for-lifecycle-management 2026-02-10T19:36:37Z 0.5 https://aptar.com/en-us/resources/developing-more-sustainable-pmdis-a-qa-on-motivation-progress-and-challenges 2026-02-10T19:35:57Z 0.5 https://aptar.com/en-us/resources/feasibility-of-intranasal-delivery-of-thin-film-freeze-dried-mucoadhesive-adjuvanted-vaccine-powders 2026-02-10T19:35:05Z 0.5 https://aptar.com/en-us/resources/the-potential-and-challenge-of-nasal-vaccination 2026-02-10T19:34:11Z 0.5 https://aptar.com/en-us/resources/under-pressure-finding-a-more-sustainable-future-for-pmdis 2026-02-10T19:33:35Z 0.5 https://aptar.com/en-us/resources/leak-detection-for-finished-sterile-containers 2026-02-10T19:33:01Z 0.5 https://aptar.com/en-us/resources/meeting-an-unmet-need-in-pre-clinical-pulmonary-research 2026-02-10T19:32:35Z 0.5 https://aptar.com/en-us/resources/putting-their-health-in-their-hands-enhancing-respiratory-patient-outcomes-through-digital-therapeutics 2026-02-10T19:32:00Z 0.5 https://aptar.com/en-us/resources/feasibility-of-intranasal-delivery-of-thin-film-freeze-dried-monoclonal-antibodies 2026-02-10T19:31:12Z 0.5 https://aptar.com/en-us/resources/intranasal-vaccination-rationale-progress-and-challenges 2026-02-10T19:30:45Z 0.5 https://aptar.com/en-us/resources/nasal-drug-development-trends-and-challenges-with-nasal-formulations 2026-02-10T19:30:02Z 0.5 https://aptar.com/en-us/resources/etfe-coated-syringe-plunger-machinability-with-vented-insertion 2026-02-10T19:29:30Z 0.5 https://aptar.com/en-us/resources/performance-of-low-gwp-propellants-in-pmdis-filling-and-dose-evaluation 2026-02-10T19:28:55Z 0.5 https://aptar.com/en-us/resources/aptar-pharma-etfe-film-coated-syringe-plungers-protect-sensitive-injectables 2026-02-10T19:28:20Z 0.5 https://aptar.com/en-us/resources/nasal-drug-delivery-beyond-hayfever 2026-02-10T19:27:45Z 0.5 https://aptar.com/en-us/resources/delivering-a-material-difference-to-map-technology 2026-02-10T19:27:17Z 0.5 https://aptar.com/en-us/resources/why-it-is-time-to-think-different-about-nasal-delivery-of-biologics 2026-02-10T19:26:31Z 0.5 https://aptar.com/en-us/resources/delivery-device-aerosol-deposition-characterization-of-innovative-purehale-technology-targeting-the-upper-airways 2026-02-10T19:25:56Z 0.5 https://aptar.com/en-us/resources/nasal-inhalation-testing-ipac-rs-droplet-size-analysis 2026-02-10T19:25:22Z 0.5 https://aptar.com/en-us/resources/delivering-on-the-promises-of-intranasal-vaccination 2026-02-10T19:24:33Z 0.5 https://aptar.com/en-us/resources/case-study-unidose-nasal-spray-pump-for-opioid-overdose 2026-02-10T19:23:55Z 0.5 https://aptar.com/en-us/resources/delivering-on-the-growing-need-for-topical-preservative-free-ophthalmic-treatments 2026-02-10T19:23:13Z 0.5 https://aptar.com/en-us/resources/advancing-inhaled-nasal-drug-clinical-studies 2026-02-10T19:22:33Z 0.5 https://aptar.com/en-us/resources/nasal-drug-delivery-challenges-and-trends-ahead 2026-02-10T19:19:29Z 0.5 https://aptar.com/en-us/resources/intranasal-immunization-promises-and-challenges 2026-02-10T19:18:54Z 0.5 https://aptar.com/en-us/resources/towards-a-more-sustainable-future-with-pmdi-solutions 2026-02-10T19:18:28Z 0.5 https://aptar.com/en-us/resources/nasal-vaccination-promises-and-challenges 2026-02-10T19:17:50Z 0.5 https://aptar.com/en-us/resources/navigating-pmdi-reformulation-2-0 2026-02-10T19:17:20Z 0.5 https://aptar.com/en-us/resources/nasal-drug-delivery-in-vitro-anatomical-models 2026-02-10T19:16:44Z 0.5 https://aptar.com/en-us/resources/intranasal-delivery-of-thin-film-freeze-dried-vaccine-powders 2026-02-10T19:16:04Z 0.5 https://aptar.com/en-us/resources/how-high-quality-film-and-coated-elastomeric-stoppers-can-accelerate-and-derisk-your-development 2026-02-10T19:15:22Z 0.5 https://aptar.com/en-us/resources/intranasal-delivery-of-monoclonal-antibodies-via-dry-powder 2026-02-10T19:14:52Z 0.5 https://aptar.com/en-us/resources/from-pmdi-device-to-therapeutic-effect 2026-02-10T19:14:26Z 0.5 https://aptar.com/en-us/resources/optimising-preclinical-studies-for-intranasal-and-pulmonary-programmes 2026-02-10T19:13:53Z 0.5 https://aptar.com/en-us/resources/assessment-of-orbital-dpi-devices-fluticasone-propionate-performance 2026-02-10T19:13:05Z 0.5 https://aptar.com/en-us/resources/bringing-topical-drugs-to-patients-skin-managing-the-drug-delivery-ecosystem 2026-02-10T19:12:11Z 0.5 https://aptar.com/en-us/resources/nose-to-brain-drug-delivery-a-promising-future 2026-02-10T19:11:27Z 0.5 https://aptar.com/en-us/resources/airless-dispensing-an-opportunity-for-brands 2026-02-10T19:10:43Z 0.5 https://aptar.com/en-us/resources/case-study-ophthalmic-squeeze-dispenser-and-esg 2026-02-10T19:10:09Z 0.5 https://aptar.com/en-us/resources/how-digital-therapeutics-add-value-to-treatments-for-complex-conditions 2026-02-10T18:02:50Z 0.5 https://aptar.com/en-us/resources/spotlight-on-emissions-reductions-for-a-lower-co2-footprint-in-pharmaceutical-packaging 2026-02-10T18:02:10Z 0.5 https://aptar.com/en-us/resources/innovations-in-pulmonary-care-dpi-and-npli-lead-the-way 2026-02-10T18:01:32Z 0.5 https://aptar.com/en-us/resources/topical-dermal-drug-delivery-system-innovation-and-sustainability 2026-02-10T18:00:47Z 0.5 https://aptar.com/en-us/resources/kolibri-precision-inhalation-for-biologics-with-guided-breathing 2026-02-10T17:59:55Z 0.5 https://aptar.com/en-us/resources/optimizing-autoinjector-performance-for-drug-development 2026-02-10T17:58:51Z 0.5 https://aptar.com/en-us/resources/low-gwp-pmdi-qa-with-aptars-zen30-futurity-valve-solution 2026-02-10T17:58:07Z 0.5 https://aptar.com/en-us/resources/acute-migraine-relief-nose-to-brain-delivery-with-lipid-nanoparticles 2026-02-10T17:57:17Z 0.5 https://aptar.com/en-us/resources/aptar-pharma-injectable-expansion-capacity-capabilities-partnership 2026-02-10T17:56:17Z 0.5 https://aptar.com/en-us/resources/aptars-uds-the-trusted-platform-for-nasal-drug-delivery 2026-02-10T17:55:03Z 0.5 https://aptar.com/en-us/resources/primary-packaging-in-the-wake-of-annex-1 2026-02-10T17:54:04Z 0.5 https://aptar.com/en-us/resources/the-nasal-drug-delivery-journey-from-systemic-to-nose-to-brain 2026-02-10T17:53:09Z 0.5 https://aptar.com/en-us/resources/intranasal-insulin-for-alzheimer-s-advancing-brain-targeted-delivery 2026-02-10T17:51:49Z 0.5 https://aptar.com/en-us/resources/subcutaneous-injections-new-dimension-for-an-enhanced-injection-experience 2026-02-10T17:50:48Z 0.5 https://aptar.com/en-us/resources/unlocking-therapeutic-potential-through-nasal-drug-repositioning 2026-02-10T17:48:53Z 0.5 https://aptar.com/en-us/resources/orbital-dpi-high-payload-patient-centric-pulmonary-drug-delivery 2026-02-10T17:48:03Z 0.5 https://aptar.com/en-us/resources/interview-a-structured-approach-to-the-eco-design-process 2026-02-10T17:45:47Z 0.5 https://aptar.com/en-us/resources/aptar-pharma-expanded-its-r-d-center-accelerating-innovation 2026-02-10T17:44:11Z 0.5 https://aptar.com/en-us/resources/achieving-clinical-success-with-pulmonary-delivery-for-biologics 2026-02-10T17:41:35Z 0.5 https://aptar.com/en-us/resources/usp-382-achieving-optimal-injectable-packaging-performance 2026-02-10T17:40:57Z 0.5 https://aptar.com/en-us/resources/growing-confidence-in-airless-dispensing 2026-02-10T17:40:09Z 0.5 https://aptar.com/en-us/resources/helping-pharma-manufacturers-meet-new-annex-1-requirements 2026-02-10T17:38:00Z 0.5 https://aptar.com/en-us/resources/consumer-driven-path-to-circularity-and-future-pharmaceutical-packaging 2026-02-10T15:42:33Z 0.5 https://aptar.com/en-us/resources/aptar-pharma-discusses-intranasal-drug-delivery-with-pharmtech 2026-01-30T20:02:54Z 0.5 https://aptar.com/en-us/resources/aptar-beauty-introduces-a-versatile-trigger-spray-portfolio-for-home-care-and-beyond 2026-01-08T13:38:12Z 0.5 https://aptar.com/en-us/resources/register-of-sustainability-certificates 2025-11-18T22:11:49Z 0.5 https://aptar.com/en-us/resources/2024-task-force-on-climate-related-financial-disclosure-tcfd 2025-11-17T17:50:14Z 0.5 https://aptar.com/en-us/resources/supplier-sustainability-engagement-playbook 2025-11-04T14:56:13Z 0.5 https://aptar.com/en-us/resources/spring-2023-supplier-sustainability-engagement-playbook 2025-10-29T09:19:11Z 0.5 https://aptar.com/en-us/resources/2025-cdp-corporate-questionnaire 2025-10-16T16:43:40Z 0.5 https://aptar.com/en-us/resources/2024-gri-index 2025-10-16T16:42:02Z 0.5 https://aptar.com/en-us/resources/2025-un-global-compact-communication-on-progress 2025-10-16T16:38:51Z 0.5 https://aptar.com/en-us/resources/2023-task-force-on-climate-related-financial-disclosure-tcfd 2025-09-29T08:51:36Z 0.5 https://aptar.com/en-us/resources/2022-gri-index 2025-07-26T16:48:49Z 0.5 https://aptar.com/en-us/resources/2021-gri-index 2025-07-26T16:47:10Z 0.5 https://aptar.com/en-us/resources/2021-sustainability-accounting-standards-board-sasb-index 2025-07-26T16:46:03Z 0.5 https://aptar.com/en-us/resources/2022-united-nations-global-compact-report 2025-07-26T16:41:25Z 0.5 https://aptar.com/en-us/resources/global-giving-policy 2025-07-26T16:40:02Z 0.5 https://aptar.com/en-us/resources/assurance-statement-for-2014-co2-emissions-scope-1-2 2025-07-26T16:39:09Z 0.5 https://aptar.com/en-us/resources/2015-assurance-statement-for-scope-1-2-location-and-market-based-co2-emissions 2025-07-26T16:38:33Z 0.5 https://aptar.com/en-us/resources/2015-gri-index 2025-07-26T16:37:57Z 0.5 https://aptar.com/en-us/resources/aptar-site-naming-conventions 2025-07-26T16:37:08Z 0.5 https://aptar.com/en-us/resources/2018-assurance-for-scope-1-and-2-location-and-market-based-emissions 2025-07-26T16:36:08Z 0.5 https://aptar.com/en-us/resources/2019-verification-letter-for-iso-14064-1-compliant-ghg-emissions 2025-07-26T16:35:35Z 0.5 https://aptar.com/en-us/resources/2016-gri-index 2025-07-26T16:34:30Z 0.5 https://aptar.com/en-us/resources/2017-gri-index 2025-07-26T16:33:12Z 0.5 https://aptar.com/en-us/resources/2018-gri-index 2025-07-26T16:32:02Z 0.5 https://aptar.com/en-us/resources/2019-gri-index 2025-07-26T16:30:41Z 0.5 https://aptar.com/en-us/resources/2020-gri-index 2025-07-26T16:29:08Z 0.5 https://aptar.com/en-us/resources/assurance-statement-for-2014-absolute-energy-metrics 2025-07-26T16:26:48Z 0.5 https://aptar.com/en-us/resources/2014-gri-index 2025-07-26T16:26:08Z 0.5 https://aptar.com/en-us/resources/2015-assurance-statement-for-absolute-energy-scope-1-2-emissions-and-renewable-energy 2025-07-26T16:25:20Z 0.5 https://aptar.com/en-us/resources/2016-assurance-for-scope-1-and-2-location-and-market-based-emissions 2025-07-26T16:24:30Z 0.5 https://aptar.com/en-us/resources/2018-assurance-for-absolute-energy-scope-1-and-2-emissions-renewables 2025-07-26T16:23:31Z 0.5 https://aptar.com/en-us/resources/2019-verification-assurance-statement-for-scope-1-2-and-3-emissions 2025-07-26T16:22:30Z 0.5 https://aptar.com/en-us/resources/2023-united-nations-global-communication-on-progress 2025-07-17T20:45:58Z 0.5 https://aptar.com/en-us/resources/2024-verification-statement-for-iso-14064-1-compliant-greenhouse-gas-emissions 2025-07-17T20:35:26Z 0.5 https://aptar.com/en-us/resources/inclusion-equity-belonging-policy 2025-06-18T16:21:07Z 0.5 https://aptar.com/en-us/resources/2024-sustainability-report-and-gri-index 2025-06-18T13:42:42Z 0.5 https://aptar.com/en-us/resources/clean-enjoyable 2025-05-15T13:50:47Z 0.5 https://aptar.com/en-us/resources/a-flavorful-squeeze 2025-05-15T13:50:46Z 0.5 https://aptar.com/en-us/resources/revolutionizing-cooking-in-india 2025-05-15T13:50:44Z 0.5 https://aptar.com/en-us/resources/design-meets-function 2025-05-15T13:50:42Z 0.5 https://aptar.com/en-us/resources/turning-categories-upside-down 2025-05-15T13:50:41Z 0.5 https://aptar.com/en-us/resources/sour-cream-revolution 2025-05-15T13:50:40Z 0.5 https://aptar.com/en-us/resources/2020-sustainability-report-and-gri-index 2025-04-04T19:09:00Z 0.5 https://aptar.com/en-us/resources/2017-assurance-for-scope-1-and-2-location-and-market-based-emissions 2025-04-04T19:03:14Z 0.5 https://aptar.com/en-us/resources/2021-sustainability-report-and-gri-index 2025-04-04T18:41:25Z 0.5 https://aptar.com/en-us/resources/2023-sustainability-accounting-standards-board-sasb-index 2025-04-04T18:26:29Z 0.5 https://aptar.com/en-us/resources/2016-assurance-for-absolute-energy-scope-1-and-2-emissions-renewables 2025-04-03T08:39:15Z 0.5 https://aptar.com/en-us/resources/2017-assurance-for-absolute-energy-scope-1-and-2-emissions-renewables 2025-04-03T08:37:04Z 0.5 https://aptar.com/en-us/resources/human-rights-policy 2025-04-03T08:31:08Z 0.5 https://aptar.com/en-us/resources/environment-health-and-safety-policy 2025-04-03T08:26:41Z 0.5 https://aptar.com/en-us/resources/sbti-certificate 2025-04-03T08:08:04Z 0.5 https://aptar.com/en-us/resources/peace-of-mind-comes-with-safety 2025-03-27T19:43:16Z 0.5 https://aptar.com/en-us/resources/one-handed-convenience 2025-03-27T19:43:11Z 0.5 https://aptar.com/en-us/resources/replicating-the-coffee-house-experience-at-home 2025-03-27T19:43:09Z 0.5 https://aptar.com/en-us/resources/30-years-of-ketchup-revolution 2025-03-27T19:42:59Z 0.5 https://aptar.com/en-us/resources/2019-sustainability-report-and-gri-index 2025-03-27T19:42:34Z 0.5 https://aptar.com/en-us/resources/2018-sustainability-report-and-gri-index 2025-03-27T19:42:30Z 0.5 https://aptar.com/en-us/resources/2017-sustainability-report-and-gri-index 2025-03-27T19:41:56Z 0.5 https://aptar.com/en-us/resources/2016-sustainability-report-and-gri-index 2025-03-27T19:41:54Z 0.5 https://aptar.com/en-us/resources/2015-sustainability-report 2025-03-27T19:41:50Z 0.5 https://aptar.com/en-us/resources/2014-sustainability-report 2025-03-27T19:41:45Z 0.5 https://aptar.com/en-us/resources/2013-sustainability-overview 2025-03-27T19:41:40Z 0.5 https://aptar.com/en-us/resources/the-covid-19-catalyst-how-a-global-pandemic-is-accelerating-the-need-for-digital-health 2025-03-27T19:41:27Z 0.5 https://aptar.com/en-us/resources/2020-cdp-climate-change-response 2025-03-27T19:41:23Z 0.5 https://aptar.com/en-us/resources/2020-cdp-water-security-response 2025-03-27T19:41:21Z 0.5 https://aptar.com/en-us/resources/2020-verification-letter-for-iso-14064-1-compliant-ghg-emissions 2025-03-27T19:41:14Z 0.5 https://aptar.com/en-us/resources/2020-verification-assurance-statement-for-scope-1-2-and-3-emissions 2025-03-27T19:41:12Z 0.5 https://aptar.com/en-us/resources/2021-united-nations-global-compact-report 2025-03-27T19:41:11Z 0.5 https://aptar.com/en-us/resources/2021-cdp-climate-change-response 2025-03-27T19:41:02Z 0.5 https://aptar.com/en-us/resources/2021-cdp-water-security-response 2025-03-27T19:41:00Z 0.5 https://aptar.com/en-us/resources/sustainability-accounting-standards-board-sasb-index 2025-03-27T19:40:58Z 0.5 https://aptar.com/en-us/resources/north-america-food-beverage-product-catalogue 2025-03-27T19:40:50Z 0.5 https://aptar.com/en-us/resources/plastics-treaty-position 2025-03-27T19:40:28Z 0.5 https://aptar.com/en-us/resources/2021-verification-assurance-statement-for-ghg-emissions-renewable-energy-waste-and-water 2025-03-27T19:39:50Z 0.5 https://aptar.com/en-us/resources/2021-verification-letter-for-iso-14064-1-compliant-ghg-emissions-2 2025-03-27T19:39:48Z 0.5 https://aptar.com/en-us/resources/2020-task-force-on-climate-related-financial-disclosure-tcfd 2025-03-27T19:39:38Z 0.5 https://aptar.com/en-us/resources/2022-carbon-transition-plan 2025-03-27T19:39:27Z 0.5 https://aptar.com/en-us/resources/2022-cdp-climate-change-response 2025-03-27T19:39:25Z 0.5 https://aptar.com/en-us/resources/2022-cdp-water-security-response 2025-03-27T19:39:24Z 0.5 https://aptar.com/en-us/resources/2021-task-force-on-climate-related-financial-disclosure-tcfd 2025-03-27T19:39:22Z 0.5 https://aptar.com/en-us/resources/2022-verification-letter-for-iso-14064-1-compliant-ghg-emissions 2025-03-27T19:38:28Z 0.5 https://aptar.com/en-us/resources/2022-sustainability-accounting-standards-board-sasb-index 2025-03-27T19:38:26Z 0.5 https://aptar.com/en-us/resources/2022-sustainability-report-and-gri-index 2025-03-27T19:38:24Z 0.5 https://aptar.com/en-us/resources/2023-aptar-climate-transition-plan 2025-03-27T19:37:54Z 0.5 https://aptar.com/en-us/resources/2023-cdp-climate-change-response 2025-03-27T19:37:52Z 0.5 https://aptar.com/en-us/resources/2023-cdp-water-security-response 2025-03-27T19:37:51Z 0.5 https://aptar.com/en-us/resources/2022-task-force-on-climate-related-financial-disclosure-tcfd 2025-03-27T19:37:50Z 0.5 https://aptar.com/en-us/resources/2023-verification-statement-for-iso-14064-1-compliant-greenhouse-gas-emissions 2025-03-27T19:37:13Z 0.5 https://aptar.com/en-us/resources/2023-sustainability-report-and-gri-index 2025-03-27T19:37:12Z 0.5 https://aptar.com/en-us/resources/2023-gri-index 2025-03-27T19:37:09Z 0.5 https://aptar.com/en-us/resources/pfas-program 2025-03-27T19:36:52Z 0.5 https://aptar.com/en-us/resources/2024-cdp-corporate-questionnaire 2025-03-27T19:36:41Z 0.5